Abattis Bioceuticals Corp. (OTCQB: ATTBF) is a cannabis biotechnology company, which focuses on the cultivation, licensing, marketing of proprietary strains, compounds, patented equipment, and consulting services for the medical marijuana industry. Shares of the cannabis biotech company are gaining 11.92%, through afternoon trading on Thursday, April 6, 2017. Over the past three months, Abattis Bioceuticals Corp. has seen average daily volume of 850,770 shares. However, volume of 925,645 shares or dollar volume of $155,971, has already exchanged hands on Thursday.

Shares of Abattis Bioceuticals Corp. are increasing Thursday, after the company announced it has been added to the North American Marijuana Index, which is a subset of the biotechnology sector. The guidelines required to be added include: $30 million market cap minimum and daily trading volumes of above $400,000. Here is the full press release detailing of the indexing news:

Abattis Bioceuticals Corp. Press Release:

VANCOUVER, BC / ACCESSWIRE / April 6, 2017 / Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”), is pleased to announce it has officially been added to The Marijuana Index, within the Biotechnology sector.

The North American Marijuana Index tracks the leading public cannabis companies operating in the United States and Canada and gives investors up to date, centralized news on the securities deemed to be well positioned within the multi-billion dollar cannabis industry. Selected companies must meet stringent trading guidelines including having a minimum market capitalization of $30 million and daily trading volumes of above $400K.

“We are delighted to have Abattis added to the The Marijuana Index and look forward to sharing our story with investors closely tracking this exciting sector,” stated Abattis CFO, Rene David. “As we approach sector legalization, we’ll start to see markets broaden their reach from the closely covered cultivation and growing players to those advancing the technology and biosciences side of the cannabis industry,” added Mr. David.

Abattis’ subsidiary Northern Vine Labs is set to open its doors this month and will legally be able to test dried plant products, extracts, derivatives and edibles for licensed producers and patients under the ACMPR regulatory framework. Management will continue to provide timely updates on these developments in the coming weeks.

About Abattis Bioceuticals Corp.

Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

About Northern Vine Canada, Inc.

Northern Vine Labs™ is licensed by Health Canada (Dealers License) for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian Cannabis market.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

Add a Comment to this Post

comments